不间断依度沙班与维生素K拮抗剂用于房颤消融:ELIMINATE-AF试验
ELIMINATE-AF是一项多国、多中心、随机、开放标签、平行组研究,评估房颤导管消融患者不间断每日一次依度沙班60mg(需减量者30mg)与维生素K拮抗剂(VKA)的安全性和有效性。共入组632例,随机614例,553例接受研究药物并接受消融;主要终点(从消融结束至治疗结束90天内全因死亡、卒中或ISTH定义大出血的首次发生)在符合方案人群中依度沙班组发生率为0.3%(1例),VKA组为2.0%(2例),风险比0.16(95%CI 0.02-1.73)。结论认为不间断依度沙班治疗可作为房颤消融患者不间断VKA治疗的替代选择。
要点
- 依度沙班主要终点发生率0.3% vs VKA 2.0%,HR 0.16(95%CI 0.02-1.73)。
- 消融至治疗结束期间,依度沙班组主要终点事件2.7%,VKA组1.7%。
- 脑微栓塞检出率依度沙班组13.8%,VKA组9.6%(名义P=0.62)。
核心结论
- 在房颤导管消融患者中,不间断依度沙班治疗可作为不间断VKA治疗的替代选择。
研究设计与样本
- ELIMINATE-AF为多国、多中心、随机、开放标签、平行组研究。
- 共入组632例,随机614例(依度沙班:VKA=2:1),553例接受研究药物并接受消融。
- 177例受试者接受脑磁共振成像评估无症状脑梗死。
- 依度沙班每日一次60mg(需减量者30mg),对照为维生素K拮抗剂(VKA)。
- 主要终点为消融结束至治疗结束(90天)内全因死亡、卒中或ISTH定义大出血的首次发生(符合方案人群)。
主要发现
- 符合方案人群中,主要终点仅发生大出血,依度沙班组0.3%(1例),VKA组2.0%(2例),HR 0.16(95%CI 0.02-1.73)。
- 消融人群(改良意向治疗,含接受消融患者)中,从消融开始至治疗结束,依度沙班组主要终点发生率2.7%(10例),VKA组1.7%(3例)。
- 发生1例缺血性卒中和1例出血性卒中,均在依度沙班组。
- 脑微栓塞检出率依度沙班组13.8%(16例),VKA组9.6%(5例),名义P=0.62。
临床怎么用
- 对于接受房颤导管消融的患者,可考虑不间断依度沙班治疗作为不间断VKA的替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, parallel-group study, was conducted to assess the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for dose reduction) vs. vitamin K antagonists (VKAs) in AF patients undergoing catheter ablation. Patients were randomized 2:1 to edoxaban vs. VKA. The primary endpoint (per-protocol population) was time to first occurrence of all-cause death, stroke, or International Society of Thrombosis and Haemostasis-defined major bleeding during the period from the end of the ablation procedure to end of treatment (90 days). Overall, 632 patients were enrolled, 614 randomized, and 553 received study drug and underwent ablation; 177 subjects underwent brain magnetic resonance imaging to assess silent cerebral infarcts. The primary endpoint (only major bleeds occurred) was observed in 0.3% (1 patient) on edoxaban and 2.0% (2 patients) on VKA [hazard ratio (95% confidence interval): 0.16 (0.02-1.73)]. In the ablation population (modified intent-to-treat population including patients with ablation), the primary endpoint was observed in 2.7% of edoxaban (N = 10) and 1.7% of VKA patients (N = 3) between start of ablation and end of treatment. There were one ischaemic and one haemorrhagic stroke, both in patients on edoxaban. Cerebral microemboli were detected in 13.8% (16) patients who received edoxaban and 9.6% (5) patients in the VKA group (nominal P = 0.62). CONCLUSION: Uninterrupted edoxaban therapy represents an alternative to uninterrupted VKA treatment in patients undergoing AF ablation.
引用
- Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019. PMID: 30976787. doi:10.1093/eurheartj/ehz190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。